Cereno Scientific announced that new preclinical data suggests that CS014 has the potential to enrich the toolbox of anticoagulant therapies in patients with a high risk of thrombotic events without increasing the risk of bleeding. CS014 is a novel histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator and is in preclinical development as a treatment for thrombosis prevention. The new data was presented at the 65th ASH Annual Meeting & Exposition organized by the American Society of Hematology, in San Diego, US, on December 9-12, 2023.

The study presented at the ASH Annual Meeting sought to determine if CS014, histone deacetylase (HDAC) inhibitor, either alone or in combination with the FXa inhibitor rivaroxaban, is able to effectively inhibit platelet and fibrin-rich thrombosis formation at the site of vascular injury without causing a significant increase in the bleeding risk in a mouse cremaster thrombosis model. The findings suggest that while CS014 and rivaroxaban are each effective antithrombotic agents, they work well together to minimize clot formation and CS014 in combination did not alter coagulation compared to rivaroxaban alone. Hence, CS014 has the potential to enrich the toolbox of antithrombotic therapies to prevent thrombosis without bleeding in patients with a high risk of thrombotic events.

Drug candidate CS014 is a novel HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. Preparations are currently ongoing towards a Phase I study and include completion of the preclinical development program, including a preclinical safety program that has already been completed, development and manufacturing of the investigational formulation used for oral dosing of the healthy volunteers and obtaining permission from the Swedish Medical Products Agency as well as the Ethics Committee to start the study. The Phase I study is estimated to be initiated in Sweden during the first half of 2024.